ANVISA Selects Priority Foreign Authorities to Strengthen Regulatory Confidence

Medical device regulatory process accelerated by regulatory trust

Impact for Medical Device and Drug Manufacturers The National Health Surveillance Agency (ANVISA) approved, at a meeting of the Committee for Strategic Management, Risks and Institutional Innovation (CGE), the list of priority Foreign Regulatory Authorities. This decision aims to consolidate regulatory trust (“reliance”), accelerating registration and inspection processes of medicines and medical devices in Brazil. […]

Anvisa Implements Tool to Speed ​​Up Toxicological Assessment of Pesticides

Anvisa implements RDC 950/2024 to optimize toxicological analysis of pesticides.

New rule optimizes analysis of petitions and reinforces security in pesticide regulation As of January 2, 2025, Anvisa’s Collegiate Board Resolution (RDC) 950/2024 comes into force, establishing complementary requirements to optimize the toxicological evaluation of pesticides formulated from equivalent technical products. The measure aims to make processes more efficient, maintaining scientific rigor and ensuring safety […]

QR Group Explains CMED’s Targeted Consultation on Pricing of Advanced Therapies

Healthcare professional analyzing graphs on advanced therapy pricing.

Understand how CMED’s Directed Consultation impacts the advanced therapies market and how QR Group helps companies to adapt The Drug Market Regulation Chamber (CMED) published Call Notice 01/2025 in the Federal Official Gazette on February 7, inviting health professionals, pharmaceutical industries and other interested parties to participate in the consultation on the pricing of advanced […]

Anvisa Gets a Grade 10 Performance in Good Regulatory Practices: Understand the Impact and How QR Group Can Help in the Process

Anvisa highlighted for good regulatory practices and excellence in regulating health products.

CGU audit recognizes Anvisa’s excellence in good regulatory practices; learn how this reflects on healthcare product regulation and how QR Group supports manufacturers. The Office of the Comptroller General of the Union (CGU) recently evaluated Anvisa, along with other regulatory agencies, regarding the adoption of good regulatory practices. Anvisa stood out for meeting all the […]

QR Group Explains Changes in ANVISA Cosmetics Regulation

Anvisa postpones deadline for migration of the Cosmetics Registration Automation System to the Solicita/Datavisa platform.

Understand how the migration to the Solicita platform impacts the regularization of cosmetics in Brazil and how QR Group can assist in this process. ANVISA announced the extension of the deadline for the migration of the Cosmetics Registration Automation System (SGAS) to the Solicita/Datavisa platform. With the effectiveness of RDCs 949/2024 and 951/2024, the new […]

Evolution of Regulation for Rare Disease Drugs in Brazil

ANVISA regulation boosts approval of drugs for rare diseases in Brazil.

Understand how ANVISA’s regulation has accelerated the approval of drugs for rare diseases and the impact on international manufacturers. Health regulation in Brazil has undergone significant advances in recent years. One of the most impacted sectors is medicines for rare diseases, which registered a significant growth in the number of approvals by ANVISA. In the […]

Regularization of Cannabis-Based Products for Veterinary Use

Illustrative image on the regulation of Cannabis products for veterinary use according to ANVISA and MAPA.

Understand how the new measure impacts the regulation of veterinary products and how QR Group can help companies in the process. On October 30, ANVISA’s Collegiate Board approved a measure that allows the regularization of cannabis-based products for veterinary use by the Ministry of Agriculture and Livestock (MAPA). The decision amends Ordinance SVS/MS 344/1998, allowing […]

Elevidys® Approval by ANVISA: The Impact of Gene Therapy for Duchenne Muscular Dystrophy

Approval of Elevidys® by ANVISA for the treatment of Duchenne Muscular Dystrophy, innovative gene therapy.

Understand the Approval of Elevidys and How QR Group Assists® in the Registration Process of Innovative Products in Brazil The approval of Elevidys® (delandistrogen moxeparvoveque) by ANVISA for the treatment of Duchenne Muscular Dystrophy (DMD) represents a milestone in the area of advanced therapies in Brazil. QR Group, with its expertise in medical device and […]

QR Group Explains Anvisa’s New Rules for Importing Medical Device Components

ANVISA update on the import and storage of medical device components – RDC 860/2024 and 939/2024

Understand how the updates to RDCs 860/2024 and 939/2024 impact the import and storage of medical device components and accessories in Brazil Anvisa has updated the processes and flows related to the import and storage of medical device components. With the recent publication of Collegiate Board Resolutions (RDCs) 860/2024 and 939/2024, importers need to understand […]

Update on Smoking Product Registration and Renewal: What Companies Need to Know

ANVISA guidelines on registration and renewal of smoking products according to RDC 896/2024

Understand how the update of ANVISA’s guidelines affects the registration and renewal of smoking products and how QR Group can help in the process. ANVISA recently updated its guidelines on the registration and renewal of smoking products derived from tobacco. This change is included in the Collegiate Board Resolution (RDC) 896/2024, which reformulates the requirements […]